Biosig Technologies (NASDAQ:STEX) Chairman Morgan Lee Lekstrom Purchases 147,000 Shares of Stock

Biosig Technologies, Inc. (NASDAQ:STEX) Chairman Morgan Lee Lekstrom purchased 147,000 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was acquired at an average price of $1.04 per share, for a total transaction of $152,880.00. Following the purchase, the chairman owned 269,500 shares in the company, valued at $280,280. This trade represents a 120.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Morgan Lee Lekstrom also recently made the following trade(s):

• On Tuesday, April 14th, Morgan Lee Lekstrom sold 12,759 shares of Biosig Technologies stock. The shares were sold at an average price of $1.07, for a total value of $13,652.13.

Biosig Technologies Trading Up 3.7%

STEX opened at $1.13 on Friday. Biosig Technologies, Inc. has a 1-year low of $0.70 and a 1-year high of $14.11. The firm has a fifty day simple moving average of $1.19. The company has a market cap of $204.69 million, a PE ratio of -0.12 and a beta of 1.58.

Biosig Technologies (NASDAQ:STEX) last posted its quarterly earnings results on Thursday, May 14th. The company reported $999.00 earnings per share for the quarter.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Wall Street Zen cut Biosig Technologies from a “hold” rating to a “strong sell” rating in a research note on Sunday, April 5th. Weiss Ratings raised Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. Finally, Needham & Company LLC decreased their price objective on Biosig Technologies from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.